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Approximately one half of patients who undergo antiviral therapy for chronic hepatitis C
virus (HCV) genotype 1 infection do not respond to treatment. African Americans (AAs)
are less responsive to treatment than Caucasian Americans (CAs), but the reasons for this
disparity are largely unknown. Recent studies suggest that serum lipids may be associated
with treatment response. The aims of this study were to evaluate baseline and changes in
serum lipids during therapy, determine whether serum lipids are associated with virologi-
cal response, and assess whether these measures explain the racial difference in efficacy.
The study participants were from Virahep-C, a prospective study of treatment-naı̈ve
patients with genotype 1 HCV infection who received peginterferon (PEG-IN) alfa-2a plus
ribavirin therapy for up to 48 weeks. Fasting serum lipids were analyzed at baseline and
during and after therapy in 160 AAs and 170 CAs. A relative risk (RR) model was
employed to evaluate characteristics associated with sustained virological response (SVR).
Antiviral therapy was associated with changes in serum lipids during and after antiviral
therapy, with the changes differing by race and the amount of PEG-IFN taken. Baseline
lipid measures independently associated with higher rates of SVR were lower triglyceride
and higher low-density lipoprotein cholesterol, with an interaction between high-density
lipoprotein cholesterol (HDLc) and gender. Lipid measures did not contribute signifi-
cantly to an explanation of the racial difference in SVR. Conclusion: Serum lipids are asso-
ciated with SVR, although these paramaters did not explain the racial difference in
treatment response. The results of this study are compatible with proposed biological
mechanisms of HCV entry, replication, and secretion, and may underscore new potential
therapeutic targets for HCV eradication. (HEPATOLOGY 2010;52:854-863)
I
n the United States, chronic hepatitis C virus
(HCV) infection is a major public health problem
afflicting 3.6 million people with direct health care
costs, including liver transplantation, exceeding $1 bil-
lion annually.1,2 The current standard of treatment of
combination peginterferon (PEG-IFN) and ribavirin is
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not completely effective in patients with hepatitis C
genotype 1, the predominant viral type in the United
States; approximately 46% people on combination
therapy achieve sustained virological response (SVR).3
Moreover, there is a racial difference in response: Afri-
can Americans (AAs) have a significantly lower
response to combination treatment compared with
Caucasian Americans (CAs).4-6 The factors that
explain this racial disparity in efficacy are largely
unknown.4
Changes in serum lipid levels during interferon ther-
apy have been reported, although the results are incon-
sistent and differ by HCV genotype. Interferon ther-
apy has been associated with increases in total
cholesterol (TC) and triglyceride (TG) levels, with TC
levels remaining significantly higher and TG levels
returning to pretreatment levels after stopping therapy.7
Other work has found significant increases in TG levels,
and no significant change in TC levels.8 Compared
with pretreatment, significant increases in TC have been
reported in a subgroup with HCV genotype 3, but not
genotype 1 during therapy,9 whereas another study
reported higher TG levels during therapy in a group
with genotype 1, but not in non–genotype 1.8
Recent studies further suggest that pretreatment
serum lipid measures may be important predictors of
treatment response. Several studies indicate that high
pretreatment low-density lipoprotein cholesterol
(LDLc) and TC levels are associated with higher rates
of SVR in multivariable analyses.10-14 In addition,
higher pretreatment TG levels have also been reported
among virological responders compared with nonres-
ponders.7 These studies further suggest that associa-
tions between lipid measures and virological response
may be specific to HCV genotype 1 and possibly ge-
notype 2. Little is known about the association
between changes in lipid measures while on therapy
and treatment response.
Observations from in vitro studies suggest relation-
ships between lipoproteins and HCV that are impor-
tant for mechanisms of viral entry into hepatocytes,
viral replication, and secretion. Several studies suggest
that HCV may combine with lipoproteins in the
serum, possibly obscuring the virus from the host
immune response, which may in turn help in viral
entry into the hepatocytes.15-18 Various receptors
involved in lipoprotein-viral particle entry into hepato-
cytes are posited, including the scavenger receptor B1
(SR-B1) and LDL receptor.19-22 Direct entry of free
HCV (i.e., not associated with lipoproteins) is also
proposed to occur through binding of the HCV enve-
lope glycoprotein E2 with SR-B1 or its human ana-
logue CD81.23-25 Within the hepatocyte endoplasmic
reticulum, studies indicate that HCV replication may be
reliant on cholesterol metabolism and a secretion pro-
cess consisting of HCV and very low-density lipoprotein
conglomerate particles.26-30 Recent work suggests that
interferon therapy leads to down-regulation of SR-B1
expression.31 This supports the notion that decreased
lipoprotein expression may in turn impact serum lipo-
protein and lipid profile measures. Therefore, associa-
tions between the serum lipids and treatment response
are supported by biologically plausible mechanisms.
This study assessed the changes in serum lipids
among patients undergoing combination therapy for
chronic hepatitis C, the relationship between serum lip-
ids (pretreatment levels and changes during treatment)
and virological response, and whether serum lipids
might explain the racial disparity in treatment efficacy.
Patients and Methods
Study Population. The participants in this study
were from the Virahep-C study, an investigation of re-
sistance to antiviral therapy for genotype 1 chronic
HCV infection, which has been described.4 In brief,
the Virahep-C study evaluated clinical, immunological,
virological, and host genetic factors that contribute to
the lack of virological response to antiviral treatment
and, in particular, the racial difference in efficacy. The
study enrolled approximately equal numbers of Cauca-
sian Americans (CAs) (n ¼ 205) and African Ameri-
cans (AAs) (n ¼ 196), all of whom underwent combi-
nation PEG-IFN and ribavirin therapy for up to 48
weeks. At 24 weeks of therapy, patients were evaluated
for the presence of HCV RNA; those with detectable
levels of HCV RNA were labeled as nonresponders
and discontinued therapy, and the remaining patients
continued therapy for an additional 24 weeks. All
patients were followed for an additional 24 weeks after
completion of therapy. The study protocol conformed
to the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a priori approval by the local
institutional review board.
Of the 401 participants enrolled in Virahep-C, lipid
profile analyses were performed among participants
who granted genetic consent (n ¼ 374) approved by
the local institutional review board and had stored
fasting serum samples at baseline (n ¼ 335). Five par-
ticipants who reported use of lipid-lowering medica-
tions were excluded from this evaluation, resulting in a
final analysis sample of 330 participants (160 AAs and
170 CAs). During treatment (24 weeks after starting
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therapy) and after treatment (24 weeks after stopping
therapy), lipid profile data were additionally available
for 253 and 245 of the participants, respectively.
Study Measures. The primary outcome for Vira-
hep-C was SVR, defined as undetectable serum HCV
RNA 24 weeks after the end of therapy. Serum lipid
measures, TG, LDLc, high-density lipoprotein choles-
terol (HDLc), and TC were obtained through analysis
of stored fasting serum samples at the Heinz Nutrition
Laboratory in the Department of Epidemiology, Uni-
versity of Pittsburgh. For serum samples with TG levels
<400 mg/dL, the Friedewald formula was used to cal-
culate LDLc indirectly (TC  HDLc  0.20  TG).32
For samples with TG levels of at least 400 mg/dL,
LDLc was assessed directly. Dyslipidemia was defined
using the cutoffs from the National Cholesterol Educa-
tion Program Adult Treatment Panel III recommenda-
tions as any of the following: LDLc 130 mg/dL,
HDLc <40 mg/dL, TC 200 mg/dL, or TG
150 mg/dL.33 A homeostasis model assessment
(HOMA) variable, HOMA2, was calculated using fast-
ing insulin and glucose measures with a Microsoft
Excel HOMA2 calculator and insulin resistance was
defined as a score 2.34 Hepatic inflammation and
fibrosis were assessed using the criteria of the histologi-
cal activity index by a single hepatopathologist.35,36
The amount of PEG-IFN and ribavirin taken by partic-
ipants was estimated using data from the Medication
Event Management System (Aardex, Zug, Switzerland).37
Statistical Analysis. Categorical measures were
summarized as frequencies and percents with differen-
ces across nominally classified groups (race, gender,
health insurance status, employment status, smoking
status, alcohol consumption of at least 2 drinks per
week, history of diabetes and hypertension, HCV ge-
notype, and severe fibrosis) assessed using a Pearson’s
chi-square test or the exact equivalent. Differences in
categorical measures across ordinal groups (i.e., educa-
tional attainment and iron scores) were assessed using
a Jonckeere-Terpstra test, or the exact equivalent. Con-
tinuous measures were summarized as medians and
interquartile ranges with differences in group distribu-
tions assessed using a Wilcoxon rank sum test (for
comparison of two groups) or a Kruskal-Wallis test
(for comparison of more than two groups). To assess
whether changes in lipid profile measures significantly
differed from baseline, a Wilcoxon sign rank test was
used. Associations between the proportion of PEG-
IFN and ribavirin taken with changes in serum lipids
were assessed using Spearman’s correlation analyses.
For all statistical tests, P < 0.05 was considered statis-
tically significant.
To evaluate factors associated with SVR, a relative
risk model was employed with a robust variance esti-
mator.38 In regression models, TG, HDLc, and TC
were transformed to the natural logarithm scale to
achieve normality. All continuous predictors were cen-
tered. The relationships between baseline and 24-week
changes during treatment in lipid profile measures and
the probability of SVR were graphically assessed using
smoothing spline plots. Due to different patterns
observed by gender, smoothing spline plots for HDLc
were examined separately for males and females. Two
types of multivariable models of SVR were constructed
using a stepwise approach. One type of multivariable
model (models 1 and 2) allowed pretreatment charac-
teristics and the amount of PEG-IFN taken during the
first 24 weeks as eligible predictors. Model 2 allowed
as additional eligible predictors the baseline lipid pro-
file measures. A second type of multivariable model
(model 3) also adjusted for body weight changes and
allowed for the inclusion of variables representing base-
line and changes in lipid profile measures during the first
24 weeks of therapy as eligible predictors. To compare
the prediction of multivariable models, differences in
area under the receiver operating curves (AUROCs) were
assessed using a nonparametric method.39
Results
Baseline characteristics of the 330 participants are
shown in Table 1. AAs did not significantly differ
from CAs by age, gender, employment status, health
risk behaviors (smoking status and weekly alcohol con-
sumption), viral level, aspartate aminotransferase, inter-
national normalized ratio, white blood cell count, pla-
telet count, percent iron/total iron-binding capacity,
Ishak fibrosis, total histological activity index score, stea-
tosis, TG, HDLc, or TC. Compared with CAs, a larger
percentage of AAs had health insurance coverage (87%
versus 78%, P ¼ 0.04), public health insurance (31%
versus 18%, P ¼ 0.006), less education (P ¼ 0.008),
history of diabetes (15% versus 4%, P < 0.001), insu-
lin resistance (46% versus 33%, p ¼ 0.02), history of
hypertension (40% versus 19%, P < 0.001), and higher
prevalence of HCV subgenotype 1b (44% versus 28%,
P ¼ 0.002). As a group, AAs had higher body mass
index (median 29.3 versus 27.4 kg/m2, P < 0.001),
higher HOMA2 scores (median 1.9 versus 1.5, P <
0.001), higher alkaline phosphatase levels (median 83
versus 78 U/L, P ¼ 0.043), higher ferritin levels (me-
dian 246 versus 149 ng/mL, P < 0.001), lower alanine
aminotransferase levels (median 60 versus 74.5 U/L,
P < 0.001), lower total bilirubin levels (median 0.06
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Table 1. Cohort Characteristics
Feature Total (N 5 330) AA (n 5 160) CA (n 5 170) P Value
Demographics
Age (years) 48 (43-52) 48 (45-52) 47 (42-52) 0.07
Male 216 (65.5) 106 (66.3) 110 (64.7) 0.77
Health insurance (m ¼ 6)* 0.008
Uninsured 58 (17.9) 21 (13.4) 37 (22.2) 0.04
Public 79 (24.4) 49 (31.2) 30 (18.0) 0.006
Private 187 (57.7) 87 (55.4) 100 (59.9) 0.42
Education (m ¼ 8)† 0.008
Less than high school 61 (18.9) 36 (23.1) 25 (15.1) 0.07
High school degree 78 (24.2) 41 (26.3) 37 (22.3) 0.16
Some college 105 (32.6) 50 (32.1) 55 (33.1) 0.16
College degree or more 78 (24.2) 29 (18.6) 49 (29.5) —
Health risk behaviors
Current smoker (m ¼ 6) 128 (39.5) 65 (41.7) 63 (37.5) 0.44
Consumes 2 alcoholic drinks/week (m ¼ 7) 66 (20.4) 38 (24.2) 28 (16.9) 0.10
General clinical features
BMI (m ¼ 5) 28.4 (25.2-32.4) 29.3 (26.6-33.9) 27.4 (24.4-31.4) 0.0002
History of diabetes 31 (9.4) 24 (15.0) 7 (4.1) 0.0007
HOMA2 (m ¼ 22) 1.7 (1.0-2.7) 1.9 (1.3-3.2) 1.5 (0.9-2.3) 0.0003
Insulin-resistant (m ¼ 22) 120 (39.0) 68 (45.6) 52 (32.7) 0.02
History of hypertension 97 (29.4) 64 (40.0) 33 (19.4) <0.0001
Viral characteristics
Log10 HCV level (m ¼ 1) 6.5 (5.6-6.7) 6.4 (5.6-6.7) 6.5 (5.6-6.8) 0.25
HCV genotype‡ 0.002
1, not otherwise specified 25 (7.6) 10 (6.3) 15 (8.8) 0.38
1a 177 (53.6) 79 (49.4) 98 (57.7) 0.13
1a/b 11 (3.3) 1 (0.6) 10 (5.9) 0.01
1b 117 (35.5) 70 (43.8) 47 (27.7) 0.002
Liver disease indicators
ALT (IU/L) 69 (45-108) 60 (40-88) 74.5 (52-139) <0.0001
AST (IU/L) 52 (37-79) 51.5 (35.5-71.5) 53 (38-87) 0.08
Alkaline phosphatase (IU/L) 79 (62-103) 83 (62-108) 78 (63-96) 0.043
Total bilirubin (mg/dL) 0.6 (0.5-0.8) 0.6 (0.4-0.8) 0.7 (0.5-0.9) 0.004
INR (m ¼ 2) 1.0 (0.9-1.1) 1.0 (0.9-1.1) 1.0 (0.9-1.1) 0.95
WBC count (103/mL) (m ¼ 3) 6.0 (4.7-7.3) 5.7 (4.6-7.3) 6.25 (4.9-7.4) 0.055
Platelet count (103/mL) (m ¼ 4) 207.5 (161-257) 212 (159-268) 207 (161-242) 0.33
Ferritin (ng/mL) (m ¼ 2) 204 (96.8-366) 246 (122-422) 149 (78-287) 0.0001
Albumin (g/dL) (m ¼ 2) 4.2 (4.0-4.4) 4.2 (3.9-4.4) 4.2 (4.0-4.5) 0.004
Iron/TIBC (m ¼ 8) 34.1 (26.2-44.0) 33.9 (25.7-41.9) 34.3 (26.4-47.7) 0.18
Ishak fibrosis score (m ¼ 1) 2 (1-3) 2 (1-3) 2 (1-3) 0.85
Ishak fibrosis score 3 (m ¼ 1) 123 (37.4) 58 (36.5) 65 (38.2) 0.74
Fat score (m ¼ 1) 0 (0-1) 0 (0-1) 0 (0-1) 0.19
Steatosis (>5 present) (m ¼ 1) 209 (63.5) 97 (61.0) 112 (65.9) 0.36
Total HAI inflammation (m ¼ 1) 8 (6-10) 8 (7-10) 9 (6-11) 0.58
Iron score (m ¼ 35) 0.09
0 157 (53.2) 66 (47.5) 91 (58.3)
1 115 (39.0) 62 (44.6) 53 (34.0)
2 23 (7.8) 11 (7.9) 12 (7.7)
Serum lipid measures
TG (mg/dL) 102.5 (75-146) 105.5 (74.5-151) 98.5 (76-137) 0.21
LDLc (mg/dL) 115.1 (88.1-137.3) 106.4 (83.4-133.4) 118.7 (95.8-141.5) 0.009
HDLc (mg/dL) 41.8 (33.7-53.8) 42.3 (32.9-54.6) 41.3 (33.8-52.0) 0.66
TC (mg/dL) 185 (157-207) 179 (153.5-204.5) 187 (161-209) 0.10
Dyslipidemia 232 (70.3) 110 (68.8) 122 (71.8) 0.55
Data for each categorical variable are presented as n (%) with P values determined using Pearson’s chi-square test (nominal variables) or the Jonck-
heere-Terpstra test (ordinal variables) or exact equivalents, where appropriate. Data for each continuous variable are presented as the median (inter-
quartile range) with P values determined using a Wilcoxon rank sum test. Where the global P value is <0.05, P values were determined using
Pearson’s chi-square test with comparisons as follows.
*Each health insurance status category compared with other categories combined.
†Less than high school versus high school degree or more; high school degree versus more than high school degree; some college versus more than some college.
‡Each genotype compared with other categories combined.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HAI, histological activity index; INR, international normal-
ized ratio; m, number with missing data; TIBC, total iron-binding capacity; WBC, white blood cell.
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versus 0.07 mg/dL, P ¼ 0.004), lower albumin levels
(median 4.2 versus 4.2 g/dL, P ¼ 0.004), and lower
LDLc levels (median 106.4 versus 118.7 mg/dL, P ¼
0.009) than CAs. The prevalence of dyslipidemia was
70% overall and did not significantly differ by race.
Compared with pretreatment, there were significant
changes in serum lipids during therapy and after com-
pletion of therapy (Fig. 1). During the initial 24 weeks
of therapy, TG levels increased significantly (median
þ30 mg/dL), in contrast to significant declines in
LDLc (14.8 mg/dL), HDLc (median 8 mg/dL),
and TC (median 17 mg/dL) (P < 0.0001 for all).
After therapy, statistically significant changes in lipid
measures were limited only to the 24-week virological
responders. Among 177 participants who underwent a
48-week course of therapy (24-week virological res-
ponders), posttreatment TG levels remained signifi-
cantly higher than pretreatment levels (median
þ8 mg/dL, P ¼ 0.03), as did posttreatment LDLc
(median þ7.2 mg/dL, P < 0.0001) and TC levels
(median þ9 mg/dL, P < 0.0001), whereas HDLc lev-
els did not significantly change (median þ0.8 mg/dL,
P ¼ 0.47). Among 62 participants who underwent a
24-week course of therapy before stopping therapy (24-
week virological nonresponders), there were no significant
changes in posttreatment serum lipids compared with pre-
treatment levels (TG, median þ9 mg/dL, P ¼ 0.41;
LDLc, median 3.2 mg/dL, P ¼ 0.36; TC, median
3 mg/dL, P¼ 0.50; HDLc,þ0.3 mg/dL, P ¼ 0.99).
The proportion of PEG-IFN taken was significantly
and directly associated with declines in LDLc (r ¼
0.22, P ¼ 0.005) and TC levels (r ¼ 0.17, P ¼
0.008) during the initial 24 weeks of therapy. The pro-
portion of ribavirin taken was not significantly associ-
ated with any changes in serum lipid levels (P > 0.05
for all). Race was significantly associated with changes
in serum lipids during the first 24 weeks of therapy.
Compared with CAs, AAs had significantly greater
increases in TG and declines in LDLc levels (P ¼
0.003 and P < 0.0001, respectively) (Fig. 2). The pat-
terns of decreases in TC levels by race were similar to
LDLc changes, although the differences were not stat-
istically significant (P ¼ 0.054).
Baseline characteristics associated with SVR are
summarized in Table 2. CA race was significantly asso-
ciated with higher SVR in unadjusted analyses (RR ¼
1.92, P < 0.001, AA reference). Features inversely
related to SVR included education beyond high school
(RR ¼ 0.64, P ¼ 0.002, less than high school degree
reference), body weight (RR ¼ 0.95 per 5 kg increase,
P ¼ 0.01), insulin resistance (RR ¼ 0.63, P ¼ 0.003,
not insulin-resistant reference), the natural log of
HOMA2 (RR ¼ 0.77, P < 0.001), baseline log10
HCV level (RR ¼ 0.77, P < 0.001), and more disease
severity as measured by fibrosis (Ishak) score (RR ¼
0.90, P ¼ 0.02). Additionally, platelet count (RR ¼
1.25 per 103 cells/mm3 increase, P ¼ 0.01) and
amounts of PEG-IFN (RR ¼ 1.41 per 10% increase,
P < 0.001) and ribavirin (RR ¼ 1.25 per 10%
increase, P < 0.001) taken during the first 24 weeks
of therapy were directly related to the rate of SVR.
With regard to lipid levels, baseline TG (natural log
scale) was inversely related (RR ¼ 0.65, P ¼ 0.002)
and LDLc was directly related (RR ¼ 1.05 per 10
Fig. 1. Serum lipid profile changes during and after antiviral ther-
apy. *P < 0.05, **P < 0.0001 (Wilcoxon signed rank test for differ-
ences from zero). Boxplots exclude extreme outliers for changes in TG
levels: 768, 422, 477, 477, 562, 573, 629, and 1,678 mg/dL
on treatment; 434 mg/dL during follow-up among 6-month virological
responders. The median levels at baseline were: TG, 100 mg/dL;
LDLc, 115.5 mg/dL; HDLc, 41.1; and TC, 183. F-up, assessment 24
weeks after stopping therapy; NR, treatment week 24 virological non-
responders (24-week course of therapy) at week 48; R, treatment
week 24 virological responders (48-week course of therapy) at week
72.Tx, assessment at treatment week 24.
Fig. 2. Race and serum lipid profile changes during therapy. P val-
ues correspond to Wilcoxon rank sum tests for racial differences. Dif-
ference in lipid profile measures at treatment week 24 minus
baseline.
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mg/dL increase, P ¼ 0.002) to the rate of SVR. Base-
line HDLc and TC levels were not significantly associ-
ated with SVR.
The relationships between the probability of SVR
and baseline and changes in TG, LDLc, HDLc, and
TC and during 24 weeks of therapy are shown in Sup-
porting Information Fig. 1. Although the probability
of SVR was negatively associated with baseline TG, it
was positively related to increases in TG during ther-
apy. On the other hand, the probability of SVR was
positively associated with baseline LDLc, but negatively
associated with increases in LDLc from baseline during
24 weeks of therapy. Among males, HDLc appeared to
be inversely related to SVR rates (Supporting Informa-
tion Fig. 1C), whereas in females the relationship was
opposite (Supporting Information Fig. 1D). The proba-
bility of SVR based on baseline and on-treatment
changes in TC levels revealed similar patterns as LDLc.
In crude and race-adjusted regression models, the
relationships between variables representing the
changes in lipid profile measures (both during and
after therapy) and the rate of SVR are summarized in
Table 3. Adjusting for race, SVR rates were directly and
significantly associated with increases in TG (natural log
scale; RR ¼ 1.29, P ¼ 0.02) and declines in LDLc
(RR ¼ 0.97, P ¼ 0.02, per 5 mg/dL increase) during
24 weeks of therapy, compared with pretreatment. Post-
treatment changes from pretreatment values in both
LDLc (RR ¼ 1.04, P ¼ 0.001, per 5 mg/dL increase)
and TC (natural log scale; RR ¼ 4.10, P < 0.001) were
directly and significantly related to the rate of SVR.
The multivariable model reported by Conjeevaram
et al.4 based on 400 participants was fit for the 329
participants for whom serum lipid and covariate data
were available (Table 4). In model 1, factors signifi-
cantly associated with SVR included male gender (RR
¼ 0.80, P ¼ 0.049), Ishak fibrosis score (RR ¼ 0.90,
P ¼ 0.009), and the amount of PEG-IFN taken dur-
ing the first 24 weeks (RR ¼ 1.38, P < 0.001 per
10% dose increase). In addition, there was a significant
interaction between race and baseline viral level (P ¼
0.005), indicating that the magnitude of the inverse
relationship between viral level and the rate of SVR
differed by race, which was documented and described
graphically in a previous report based on the Virahep-
C cohort.4 Using the same eligible predictors as model
1 and also allowing the baseline lipid profile variables
to be eligible for entry, model 2 was created. In model
2, a significant interaction between HDLc and gender
(P ¼ 0.02) was found. Assessed graphically in Fig. 3A
for an AA male and female adjusting for other param-
eters in the model, whereas HDLc (natural log scale)
was inversely related to the rate of SVR for males, the
relationship was direct among females. Additional
multivariable analyses on a sample of 307 patients
with available insulin resistance data did not indicate a
significant relationship between insulin resistance
measures and SVR, accounting for other parameters in
model 2 (data not shown). The prediction of SVR did
not significantly differ between models 1 and 2
(AUROC ¼ 0.801 versus 0.811, respectively, P ¼
0.42) (Fig. 4A).
Table 2. Univariate Models of SVR and Selected Predictors
in Serum Lipid Assessment Subset
Feature RR (95% CI) P Value
CA race 1.92 (1.45-2.56) <0.001
Male gender 0.79 (0.61-1.02) 0.07
Age* 0.96 (0.89-1.04) 0.31
Years infected 1.005 (0.99-1.02) 0.54
High school education or less 0.64 (0.48-0.85) 0.002
Weight (kg)* 0.95 (0.91-0.99) 0.01
BMI (kg/m2) 0.98 (0.96-1.01) 0.23
History of diabetes 0.52 (0.27-1.01) 0.054
HOMA2† 0.77 (0.65-0.90) <0.001
Insulin-resistant 0.63 (0.46-0.86) 0.003
History of hypertension 0.76 (0.56-1.04) 0.09
Current alcohol use 0.92 (0.66-1.27) 0.60
Current smoker 1.10 (0.85-1.43) 0.48
ALT (IU/L)‡ 1.09 (0.94-1.25) 0.26
ALT (IU/L)† 1.08 (0.90-1.31) 0.40
AST (IU/L)‡ 0.83 (0.61-1.10) 0.18
AST (IU/L)† 0.83 (0.66-1.04) 0.11
INR 1.43 (0.48-4.26) 0.52
Hemoglobin (g/dL) 0.95 (0.86-1.05) 0.30
WBC count (per 103 cells/mm3) 1.05 (0.99-1.11) 0.12
Platelet count (per 105 cells/mm3) 1.25 (1.06-1.49) 0.01
Genotype 1a versus non–genotype 1a 0.88 (0.68-1.13) 0.32
Baseline viral level (IU)§ 0.77 (0.66-0.89) <0.001
Ishak fibrosis score 0.90 (0.82-0.98) 0.02
Ishak fibrosis score 3 0.82 (0.62-1.08) 0.16
Cirrhosis (fibrosis score 5-6) 0.65 (0.34-1.24) 0.20
Steatosis score 0.85 (0.67-1.07) 0.17
Steatosis (>5% present) 0.866 (0.66-1.11) 0.24
HAI inflammation score 0.995 (0.95-1.05) 0.85
Proportion of PEG-IFN takenk 1.41 (1.18-1.68) <0.001
Proportion of ribavirin takenk 1.25 (1.15-1.35) <0.001
Lipid parameters¶
TG† (mg/dL) 0.65 (0.49-0.86) 0.002
LDLc# (mg/dL) 1.05 (1.02-1.09) 0.002
HDLc§ (mg/dL) 0.96 (0.64-1.44) 0.84
TC§ (mg/dL) 1.59 (0.84-3.01) 0.15
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransfer-
ase; BMI, body mass index; CI, confidence interval; HAI, histological activity





kPer 10% increase in dose.
¶Eligible for entry in multivariable model 2.
#Per 10-unit increase.
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In multivariable modeling, model 3 was constructed
using 250 participants who had covariate, baseline
lipid profile, and treatment week 24 lipid profile data
(Table 3). Model 3 evaluated the relationships between
SVR and lipid profile changes during therapy along
with those variables eligible for entry into model 2.
Variables in models 2 and 3 were similar, though the
baseline TG (natural log scale) and LDLc levels were
not significantly associated with SVR in model 3,
whereas the change in LDLc during the first 24 weeks
was retained. Similar to model 2, there was a signifi-
cant interaction (P ¼ 0.009) in model 3 between
HDLc (natural log scale) and gender, a relationship
that was inverse among males and direct among
females (Fig. 3B). The AUROC for model 3 was not
significantly different than that of model 1 fit to the
same 250 participants (AUROC ¼ 0.799 versus
0.779, P ¼ 0.19) (Fig. 4B). In separate multivariable
assessments based on a patient subsample with avail-
able insulin resistance data (n ¼ 231) and accounting
for parameters in model 3, insulin-resistant status as a
dichotomous measure, but not HOMA2 as a continu-
ous measure, was significantly associated with SVR
(data not shown). In all three multivariable models,
race remained a significant predictor of SVR, and the
magnitude of the association changed little with the
addition of serum lipid measures.
Discussion
This evaluation of serum lipids and virological
response showed a relationship between baseline lipid




RR (95% CI) P Value RR (95% CI) P Value
D: On-treatment – baseline (n ¼ 253)
TG* (mg/dL) 1.43 (1.15-1.78) 0.001 1.29 (1.05-1.59) 0.02
LDLc† (mg/dL) 0.96 (0.92-0.98) <0.001 0.97 (0.95-0.995) 0.02
HDLc* (mg/dL) 1.13 (0.63-2.02) 0.68 1.13 (0.65-1.96) 0.66
TC* (mg/dL) 0.49 (0.23-1.08) 0.08 0.64 (0.30-1.35) 0.24
D: Follow-up – baseline (n ¼ 245)
TG* (mg/dL) 1.29 (0.98-1.70) 0.07 1.24 (0.97-1.61) 0.09
LDLc† (mg/dL) 1.04 (1.02-1.06) 0.001 1.04 (1.01-1.06) 0.001
HDLc* (mg/dL) 0.94 (0.54-1.66) 0.84 0.92 (0.54-1.58) 0.78
TC* (mg/dL) 4.64 (2.46-8.76) <0.001 4.10 (2.14-7.85) <0.001
Abbreviation: CI, confidence interval.
*Natural log transformed.
†Per 5 mg/dL change.
Table 4. Multivariate Models of SVR and Selected Predictors
Feature
Model 1 Model 2 Model 3
RR (95% CI) P Value RR (95%CI) P Value RR (95%CI) P Value
CA race 1.98 (1.47-2.67) <0.001 1.81 (1.33-2.45) <0.001 2.28 (1.58-3.30) <0.001
Male gender 0.80 (0.64-0.999) 0.049 0.81 (0.62-1.07) 0.14 0.96 (0.72-1.27) 0.76
Baseline viral level (IU)* and CA race interaction 1.51 (1.13-2.00) 0.005 1.49 (1.12-1.97) 0.006 1.72 (1.23-2.41) 0.001
Ishak fibrosis score 0.90 (0.83-0.97) 0.009 0.91 (0.83-0.98) 0.02 0.90 (0.83-0.98) 0.02
Amount of PEG-IFN taken† 1.38 (1.18-1.62) <0.001 1.37 (1.18-1.60) <0.001 0.98 (0.85-1.12) 0.77
Lipid parameters
TG‡ (mg/dL) 0.69 (0.52-0.91) 0.009
HDLc‡ (mg/dL) and male gender interaction 0.40 (0.18-0.87) 0.02 0.36 (0.16-0.77) 0.009
LDLc§ (mg/dL) 1.03 (1.001-1.07) 0.046
DLDLc§ (mg/dL) 0.97 (0.95-0.996) 0.02
Model 1 is a replication of the Conjeevaram et al.4 model on a subset of participants with available baseline serum lipid data (n ¼ 330). Model 2 includes
baseline serum lipid variables as eligible for entry. Model 3 is a multivariate model with baseline and on-treatment changes from baseline in serum lipid variables
as eligible for entry (n ¼ 253). This model also adjusts for changes in body weight (data not shown).
Abbreviation: CI, confidence interval.
*Log10 transformed.
†Per 10% increase in dose.
‡Natural log transformed.
§Per 5-unit increase.
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measurements and on-treatment changes in lipids with
antiviral response to therapy. Pretreatment TG and
LDLc levels were inversely and directly related to the
SVR rate, respectively. Baseline LDLc was significantly
higher in CAs compared with AAs. Furthermore,
changes in these two parameters during the first 24
weeks of therapy were associated with virological
response and differed significantly by race. In regression
models, several lipid profile parameters at baseline (TG
and LDLc, HDLc [with an interaction with gender])
and on-treatment changes (TG and LDLc) were signifi-
cant predictors of SVR. However, including serum lipid
measures did not significantly improve the prediction of
SVR compared with models without these measures,
nor did serum lipid measures account for the racial dif-
ference in treatment efficacy between CAs and AAs.
Few studies have assessed in detail changes in serum
lipids during and after therapy for chronic HCV
Fig. 3. (A) Predicted probabilities of SVR and HDLc by gender from
model 2. Predicted probabilities were calculated adjusting for other
parameters in the model for an individual with the following character-
istics: AA, Ishak fibrosis score of 2, took 80% of the prescribed PEG-
IFN during 24 weeks of therapy, and a mean baseline viral level of
6.3 log10 IU/mL, natural log of TG of 4.7 mg/dL, and LDLc level of
116.2 mg/dL. (B) Predicted probabilities of SVR and HDLc by gender
from model 3. Predicted probabilities were calculated adjusting for
other parameters in the model for an individual with the following
characteristics: AA, Ishak fibrosis score of 2, took 80% of the pre-
scribed PEG-IFN during 24 weeks of therapy, mean baseline viral level
of 6.3 log10 IU/mL, and on-treatment change in LDLc level from pre-
treatment of 16.8 mg/dL.
Fig. 4. (A) Receiver operator curves of multivariable models 1 and
2 (n ¼ 329). Model 1 includes race, gender, baseline viral level,
baseline viral level and race interaction, Ishak fibrosis score, and
amount of PEG-IFN taken. Model 2 includes variables in model 1 plus
baseline TG, baseline HDLc, baseline HDLc and gender interaction,
and baseline LDLc. (B) Receiver operator curves of multivariable mod-
els 1 and 3. Model 1 includes race, gender, baseline viral level, base-
line viral level and race interaction, Ishak fibrosis score, and amount
of PEG-IFN taken. Model 3 includes variables in model 1, body weight
change, baseline HDLc, baseline HDLc and gender interaction, and
change in LDLc during 24 weeks of therapy.
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infection. Compared with pretreatment, the significant
increase in TG levels during therapy found here is
consistent with findings in other studies that reported
mean increases of 45 mg/dL and 60 mg/dL in TG lev-
els.8,9 We note that compared with pretreatment, these
studies did not report significant changes in TC during
or after therapy, whereas our study found significant
declines in TC during treatment.8,9 However, the sig-
nificant increase in TC levels posttreatment compared
with pretreatment is consistent with one study that
reported an approximate 10.5 mg/dL significant mean
increase,7 whereas another study did not report signifi-
cant changes.8 The difference in findings across studies
may be due to variable sample sizes, disparate treat-
ment regimens, inclusion of patients with different
HCV genotypes, and other participant characteristics.
The direct relationship between pretreatment LDLc
levels and SVR rate is consistent with findings from
several other studies.10-14
Hamamoto et al.7 reported an association between
higher pretreatment TG levels and virological response,
which is opposite of the relationship in our study, pos-
sibly a reflection of HCV genotype or host lipid recep-
tor genetic differences. Whereas only individuals
infected with HCV genotype 1 were included in Vira-
hep-C, genotype 2 was the predominant genotype in
the previously referenced study. Single-nucleotide poly-
morphisms in the receptors involved in the serum lip-
oprotein particle uptake into hepatocytes (SR-B1 and
LDL receptors) may also account for the different rela-
tionships observed in the two study populations. In
multivariable analyses, significant interactions between
HDLc levels and gender in relation to virological
response were found, which have not been previously
reported. These relationships warrant further investiga-
tion and validation in other cohorts to clarify whether
lipid profile measures are important predictors of treat-
ment response. Posttreatment increases from baseline in
LDLc and TC were found to be associated with SVR,
which may correspond to HCV eradication and the
subsequent resolution of HCV-induced liver damage.
With evidence from in vitro work supporting several
possible mechanisms involving serum lipoproteins,
cholesterol metabolism, lipoprotein receptors, and
HCV entry, replication and secretion, the significant
relationships between both baseline and changes from
baseline LDLc and TG levels and rates of SVR are
biologically feasible.15-22,26-30 The direct relationship
between LDLc and SVR may partially be explained by
competition for LDL receptor sites preventing viral
entry into hepatocytes, increasing exposure of HCV to
the host immune response in the serum. These find-
ings suggest that serum lipids may yield some prognos-
tic value in determining the probability of treatment
success and possibly highlight new therapeutic targets.
Further prospective investigation of the impacts of die-
tary modification and lipid-lowering agents on virolog-
ical response may be warranted. Treatment trials inves-
tigating statins and fibrates to improve virological
response have yielded mixed results.40-42 As docu-
mented in the Virahep-C cohort,43 insulin resistance
may also contribute to the relationship between serum
lipids and SVR.
In conclusion, this study suggests that serum lipid
measures are predictors of SVR, but that their predic-
tive ability is ameliorated by race such that these meas-
ures do not explain the racial disparity in treatment ef-
ficacy between CAs and AAs. However, this study
underscores the potential relevance of serum lipids to
virological response. Future investigations may seek to
assess relationships between SVR, other characteriza-
tions relevant to serum lipids, and genetic determi-
nants of lipid metabolism.
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